Welcome to our dedicated page for Envveno Medical news (Ticker: NVNO), a resource for investors and traders seeking the latest updates and insights on Envveno Medical stock.
enVVeno Medical Corporation develops bioprosthetic venous valve devices for severe deep chronic venous insufficiency in the United States. News about NVNO centers on the company’s enVVe System, a minimally invasive transcatheter replacement venous valve, and its TAVVE pivotal study under FDA investigational device exemption approval.
Recurring updates also cover the VenoValve surgical replacement venous valve, FDA communications tied to device review, clinical-development planning, cash runway and operating losses, Nasdaq listing compliance, shareholder-approved capital-structure actions such as the reverse stock split, and investor communications from this late clinical-stage medical device issuer.
enVVeno Medical presented one-year data from the VenoValve U.S. pivotal trial at the 51st Annual VEITH Symposium, supporting their recent FDA pre-market authorization application. Key findings include: 85% of subjects achieved clinically meaningful benefit with a 3+ point improvement in revised Venous Clinical Severity Score (rVCSS), 7.91 point average rVCSS improvement among responders, 97% target vein patency rate, 75% median pain reduction, and 87% median ulcer area reduction.
The VenoValve demonstrated effectiveness across all CEAP diagnostic classes, with positive correlation between rVCSS improvement and systemic reflux time. The safety profile showed minimal adverse events, with 94% of subjects experiencing adverse events still achieving clinical meaningful benefit at one year.
enVVeno Medical has submitted its PMA application to the FDA for the VenoValve, seeking marketing and sales approval in the United States. Four out of five modules have been approved, with the final module containing clinical data from the SAVVE pivotal trial and proposed labeling. The FDA-designated breakthrough device aims to treat severe deep venous Chronic Venous Insufficiency (CVI), targeting an estimated 2.5 million U.S. candidates annually. A decision is expected in the second half of 2025. The company is also developing enVVe, a next-generation transcatheter-based replacement venous valve, with pivotal trials expected mid-2025.
enVVeno Medical (NASDAQ:NVNO) reported Q3 2024 financial results and progress on its VenoValve and enVVe programs. The company has submitted 4 out of 5 modules for VenoValve's FDA premarket approval (PMA) application, with the final module containing clinical data scheduled for Q4 2024. The company ended Q3 with $48.4 million in cash and investments after raising $13.6 million in September. Q3 net loss increased 12% to $5.6 million, with quarterly cash burn at $4.3 million. The GLP study for enVVe is underway, with IDE approval filing expected mid-2025.
enVVeno Medical has successfully initiated its six-month pre-clinical GLP study for enVVe, their transcatheter-delivered replacement venous valve. The first wave of implants was completed successfully, with final wave scheduled for December. The company is on track to file for IDE approval for the enVVe pivotal trial by mid-2025. The updated delivery system performed well, with improvements to crimping and delivery systems resulting in consistent valve deployment. The company plans to file its PMA application for VenoValve and release supporting data in Q4 2024, marking its transition from development to commercial stage.
enVVeno Medical (NASDAQ:NVNO) has announced the pricing of an underwritten public offering of 4,285,715 shares of its common stock (or pre-funded warrants) at $3.50 per share. The company expects to receive gross proceeds of approximately $15.0 million from the offering, excluding underwriting discounts and other expenses. The offering is expected to close around September 30, 2024.
The company plans to use the net proceeds for the continued development of its two lead products, VenoValve and enVVe, and for general corporate purposes. Titan Partners Group is acting as the sole bookrunner for the offering. enVVeno has granted the underwriter a 30-day option to purchase up to an additional 642,857 shares at the public offering price.
enVVeno Medical (NASDAQ:NVNO) has announced a proposed public offering of common stock and pre-funded warrants. The company plans to grant the underwriter a 30-day option to purchase up to an additional 15% of the offered securities. Titan Partners Group, a division of American Capital Partners, is acting as the sole bookrunner for the offering.
The net proceeds will be used primarily for the continued development of enVVeno's two lead products, VenoValve and enVVe, as well as for general corporate purposes. The offering is subject to market conditions, and there is no assurance regarding its completion or terms.
The securities will be offered under a previously filed shelf registration statement. A preliminary prospectus supplement and accompanying base prospectus will be filed with the SEC.
enVVeno Medical (Nasdaq: NVNO) has appointed Sandy Prietto as Vice President of Marketing, strengthening its commercial team ahead of key milestones. The company, focused on treating venous disease, is preparing for the VenoValve monetization and several Q4 2024 events, including:
1. Completion of PMA submission for FDA approval of VenoValve
2. Release of one-year data from VenoValve U.S. Pivotal Study
3. Initiation of GLP pre-clinical study for enVVe
Ms. Prietto brings extensive experience in medical device marketing and successful product launches. enVVeno's lead product, VenoValve, is a surgical replacement venous valve for severe Chronic Venous Insufficiency (CVI). The company is also developing enVVe, a non-surgical transcatheter-based replacement venous valve. With $39.1 million in cash and investments as of Q2, enVVeno is funded through 2025.
enVVeno Medical has made significant progress in its FDA premarket approval (PMA) application for the VenoValve, a surgical replacement venous valve. The company has successfully submitted, and the FDA has approved, four out of five modules required for the PMA application. The fifth and final module, containing clinical data from the SAVVE U.S. pivotal trial, is expected to be filed in Q4 2024.
The VenoValve is being developed as a potential treatment for severe Chronic Venous Insufficiency (CVI), a debilitating disease affecting approximately 2.5 million new patients annually in the U.S. The SAVVE study, involving 75 CVI patients across 21 U.S. sites, is currently collecting one-year clinical data to support the final PMA module submission.
As of June 30, 2024, enVVeno Medical had $39.1 million in cash and investments, which is expected to fund operations through the FDA's decision on the VenoValve PMA application.
enVVeno Medical (NASDAQ:NVNO) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- $39.1 million in cash and investments, sufficient to fund operations through end of 2025
- Positive interim venous ulcer healing data from VenoValve pivotal trial
- On track to file VenoValve FDA approval application in Q4 2024
- Progress on enVVe transcatheter-based replacement venous valve
Financial results:
- Net loss decreased by 23.1% to $5.0 million
- Cash burn of $3.8 million, better than projected $4-5 million
- R&D expenses decreased by 33.3% to $2.8 million
- SG&A expenses remained flat at $2.6 million
enVVeno Medical announced that CEO Robert Berman will participate in the Virtual Investor Closing Bell Series on June 27, 2024. The event will be webcast live at 4:00 PM ET and will feature Berman discussing positive interim data from the SAVVE U.S. pivotal trial for the VenoValve®. The data showed significant improvements in venous ulcer healing, with key safety and efficacy milestones highlighted. Berman will also outline the timeline for the anticipated approval of the VenoValve®. The presentation will include a Q&A session, and a replay will be available on enVVeno's website for 90 days.